Dr. Stephane Angers
About Dr. Stephane Angers
Dr. Angers is an expert in the field of signal transduction. He obtained his Ph.D. from the Université de Montréal in 2002 under the guidance of Dr. Michel Bouvier. His thesis work led to the development and application of light energy transfer methodology to study protein-protein interaction and signal transduction. From 2002-2006 he was a Howard Hughes Post-Doctoral Fellow at the University of Washington in Seattle under Dr. Randall T. Moon, where he identified and characterized novel components of the Wnt signaling pathway and a new class of E3 ubiquitin ligases.
In October 2006, Dr. Angers established his independent research program in the Department of Pharmaceutical Sciences at the Faculty of Pharmacy and the Department of Biochemistry at the University of Toronto. He is the recipient of the Canada Research Chair in Functional Architecture of Signal Transduction. His research program is developed to understand the signaling mechanisms underlying the Wnt and Hedgehog families of growth factors and their signaling mechanisms in development, adult tissue homeostasis, and human diseases. His pioneer work led to the development of novel antibody molecules blocking and activating the Wnt pathway for the treatment of cancers and regenerative medicine applications. He is the scientific founder of two biotech companies, ModMab Therapeutics, and AntlerA Therapeutics, which are pursuing the clinical development of these molecules.
In September 2021, Dr. Angers was named Director of the Donnelly Centre of Cellular and Biomolecular Research at the University of Toronto, an internationally recognized Research Institute bringing together multidisciplinary teams of scientists.
Dr. Stephane Angers on the web